Results of Real-World Study Show Dapagliflozin Decreases Cardiovascular Events and All-Cause Mortality Risk Compared to DPP-4 inhibitors in Patients With Type 2 Diabetes

August 3, 2017. The results of Dapagliflozin Compared to DPP-4 inhibitors is Associated with Lower Risk of Cardiovascular Events and All-cause Mortality in Type 2 Diabetes Patients (CVD-REAL Nordic) show that, in a real-world setting, patients who use dapagliflozin experience lower risk of hospital events for heart failure (HHF), major adverse cardiac events (MACE), and all-cause mortality compared with patients who receive dipeptidyl peptidase-4 inhibitors (DPP-4i). In this international registry-based study, the composite MACE outcome included cardiovascular (CV) mortality, nonfatal myocardial infarction, and nonfatal stroke. The study, conducted in Denmark, Norway, and Sweden, matched patients who were new users of dapagliflozin (n=10,227) in a 1:3 ratio with patients who were new users of DPP-4i (n=30,681). At baseline, no statistical differences were observed between the 2 groups; mean age was 61 years and CV disease was present in 23% of patients. After a mean follow-up of 0.95 years, the hazard ratios (HRs) for patients who received dapagliflozin were 0.79 (95% CI 0.67-0.94) for MACE, 0.62 (0.50-0.77) for HHF, and 0.44 (0.33-0.60) for all-cause mortality, compared with patients who received DPP-4i. Differences in HRs were not significant for stroke (0.79 [0.61-1.03]), myocardial infarction (0.91 [0.72-1.16]), or CV mortality (0.76 [0.53-1.08]). No differences were found in rates of severe hypoglycemia or atrial fibrillation. Follow this link to read the study abstract.